fast-track designation granted by FDA 2/10; data from pivotal trial expected by end of 2010
Brand Myocet Generic doxorubicin, liposomal non-pegylated
Company name Sopherion Product type Speciality
Therapeutic category Antineoplastics Key uses breast cancer, HER2 positive metastatic
Other Uses lymphoma Drug Class anthracycline
Dosage From IV Expected Approval 2011-Q4
FDA Filing N/A Last Update date March 02,2010
Link to news article
Link to clinicaltrials.gov